(VIANEWS) – Natural Health Trends Corp. (NHTC), Philip Morris International (PM), Amgen (AMGN) are the highest payout ratio stocks on this list.
We have gathered information concerning stocks with the highest payout ratio up until now. The payout ratio in itself isn’t a guarantee of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1333.33% Payout Ratio
Natural Health Trends Corp., a direct-selling and e-commerce company, provides personal care, wellness, and lifestyle products under the NHT Global brand. The company offers wellness products, including liquid, encapsulated, tableted, and powder dietary and nutritional supplements, as well as vitamins and minerals; and herbal products comprising herbal supplements. It also provides beauty products, such as anti-defying and hydrating cleansers, creams, lotions, serums, and toners; and lifestyle products, which include weight management and energy enhancing supplements. In addition, the company offers home appliances; and infant and toddler bath, oral care, hair care, and body care products. It sells its products directly to consumers, as well as through an e-commerce retail platform in the United States, Canada, Cayman Islands, Mexico, Peru, Hong Kong, Taiwan, China, Singapore, Malaysia, Thailand, Vietnam, South Korea, Japan, India, Russia, Kazakhstan, and Europe. The company was formerly known as Florida Institute of Massage Therapy, Inc. and changed its name to Natural Health Trends Corp. in June 1993. Natural Health Trends Corp. was incorporated in 1988 and is headquartered in Tsim Sha Tsui, Hong Kong.
Earnings Per Share
As for profitability, Natural Health Trends Corp. has a trailing twelve months EPS of $0.06.
Natural Health Trends Corp. has a trailing twelve months price to earnings ratio of 89.83. Meaning, the purchaser of the share is investing $89.83 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1.29%.
As maintained by Morningstar, Inc., the next dividend payment is on May 14, 2023, the estimated forward annual dividend rate is 0.8 and the estimated forward annual dividend yield is 14.84%.
Natural Health Trends Corp.’s worth is below its 50-day moving average of $5.45 and way higher than its 200-day moving average of $4.70.
90.52% Payout Ratio
Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HBLENDS, EETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, SENTIA, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe and Sampoerna A in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 73 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in Stamford, Connecticut.
Earnings Per Share
As for profitability, Philip Morris International has a trailing twelve months EPS of $5.59.
Philip Morris International has a trailing twelve months price to earnings ratio of 16.79. Meaning, the purchaser of the share is investing $16.79 for every dollar of annual earnings.
Today’s last reported volume for Philip Morris International is 3104370 which is 28.54% below its average volume of 4344420.
Yearly Top and Bottom Value
Philip Morris International’s stock is valued at $93.85 at 02:23 EST, way under its 52-week high of $109.81 and way above its 52-week low of $82.85.
Philip Morris International’s sales growth is negative 0.4% for the current quarter and 16.1% for the next.
3. Amgen (AMGN)
54.04% Payout Ratio
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Earnings Per Share
As for profitability, Amgen has a trailing twelve months EPS of $14.71.
Amgen has a trailing twelve months price to earnings ratio of 15.28. Meaning, the purchaser of the share is investing $15.28 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 252.78%.
Yearly Top and Bottom Value
Amgen’s stock is valued at $224.72 at 02:23 EST, way under its 52-week high of $296.67 and higher than its 52-week low of $223.30.
Amgen’s worth is under its 50-day moving average of $238.81 and way below its 200-day moving average of $250.99.
Today’s last reported volume for Amgen is 2295000 which is 2.8% above its average volume of 2232460.
Previous days news about Amgen (AMGN)
- : FTC sues to block Amgen’s acquisition of horizon therapeutics. According to MarketWatch on Tuesday, 16 May, "The Federal Trade Commission is suing to block biopharma giant Amgen Inc.’s proposed acquisition of Horizon Therapeutics, saying the deal would allow Amgen to "entrench the monopoly positions" of Horizon treatments for serious medical conditions. "
- FTC May reportedly block Amgen's (amgn) $28b horizon buyout. According to Zacks on Tuesday, 16 May, "The above articles also mentioned that when they contacted Amgen for comments on the above news, it stated that it will provide "appropriate updates" once more information is available.", "Last December, Amgen announced that it will acquire Horizon Therapeutics for $116.50 per share in cash or $27.8 billion. "
- According to Zacks on Wednesday, 17 May, "The FTC believes that the acquisition would allow Amgen to coax insurance companies and pharmacy benefit managers (PBMs) to favor access to Horizon’s Tepezza, a thyroid eye disease treatment, and Krystexxa, a chronic refractory gout medicine.", "The FTC believes that if Amgen succeeds in entrenching the monopoly positions of Horizon’s drugs, it would increase revenues from Tepezza and Krystexxa and boost its top line"
- FTC challenges Amgen's (amgn) $28b acquisition of horizon. According to Zacks on Wednesday, 17 May, "In response to the above lawsuit, Amgen issued a statement that it was disappointed by the FTC’s decision and does not believe that the merger poses any competitive issues. ", "The Senator accused both Amgen and Horizon Therapeutics to have been engaged in "brazen price increases on drugs that face little or no competition"."
50.17% Payout Ratio
Northern Trust Corporation, a financial holding company, provides wealth management, asset servicing, asset management, and banking solutions for corporations, institutions, families, and individuals worldwide. It operates in two segments, Asset Servicing and Wealth Management. The Asset Servicing segment offers asset servicing and related services, including custody, fund administration, investment operations outsourcing, investment management, investment risk and analytical services, employee benefit services, securities lending, foreign exchange, treasury management, brokerage services, transition management services, banking, and cash management services. This segment serves corporate and public retirement funds, foundations, endowments, fund managers, insurance companies, sovereign wealth funds, and other institutional investors. The Wealth Management segment offers trust, investment management, custody, and philanthropic; financial consulting; guardianship and estate administration; family business consulting; family financial education; brokerage services; and private and business banking services. This segment serves high-net-worth individuals and families, business owners, executives, professionals, retirees, and established privately held businesses. The company also provides asset management services, such as active and passive equity; active and passive fixed income; cash management; alternative asset classes comprising private equity and hedge funds of funds; and multi-manager advisory services and products through separately managed accounts, bank common and collective funds, registered investment companies, exchange traded funds, non-U.S. collective investment funds, and unregistered private investment funds. In addition, it offers overlay and other risk management services. Northern Trust Corporation was founded in 1889 and is headquartered in Chicago, Illinois.
Earnings Per Share
As for profitability, Northern Trust has a trailing twelve months EPS of $5.78.
Northern Trust has a trailing twelve months price to earnings ratio of 12.48. Meaning, the purchaser of the share is investing $12.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.14%.
Year-on-year quarterly revenue growth grew by 0.8%, now sitting on 6.76B for the twelve trailing months.
36.47% Payout Ratio
Auburn National Bancorporation, Inc. operates as the bank holding company for AuburnBank that provides various banking products and services in East Alabama. The company's deposit products include checking, savings, and transaction deposit accounts, as well as certificates of deposit. It also provides commercial, financial, agricultural, real estate construction, and consumer loan products; and other financial services. In addition, the company offers automated teller services; debit cards; online banking, bill payment, and other electronic services; and safe deposit boxes. It operates through seven full-service branches in Auburn, Opelika, Notasulga, and Valley, Alabama; as well as loan production offices in Auburn and Phenix City, Alabama. Auburn National Bancorporation, Inc. was founded in 1907 and is headquartered in Auburn, Alabama.
Earnings Per Share
As for profitability, Auburn National Bancorporation has a trailing twelve months EPS of $2.93.
Auburn National Bancorporation has a trailing twelve months price to earnings ratio of 7.49. Meaning, the purchaser of the share is investing $7.49 for every dollar of annual earnings.
Today’s last reported volume for Auburn National Bancorporation is 879 which is 29.56% below its average volume of 1248.
Auburn National Bancorporation’s value is under its 50-day moving average of $23.34 and under its 200-day moving average of $24.17.
As claimed by Morningstar, Inc., the next dividend payment is on Mar 8, 2023, the estimated forward annual dividend rate is 1.08 and the estimated forward annual dividend yield is 4.89%.